1. Home
  2. CNTX vs FBYD Comparison

CNTX vs FBYD Comparison

Compare CNTX & FBYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTX
  • FBYD
  • Stock Information
  • Founded
  • CNTX 2015
  • FBYD 2021
  • Country
  • CNTX United States
  • FBYD United States
  • Employees
  • CNTX N/A
  • FBYD N/A
  • Industry
  • CNTX Biotechnology: Pharmaceutical Preparations
  • FBYD
  • Sector
  • CNTX Health Care
  • FBYD
  • Exchange
  • CNTX Nasdaq
  • FBYD Nasdaq
  • Market Cap
  • CNTX 149.6M
  • FBYD 120.8M
  • IPO Year
  • CNTX 2021
  • FBYD N/A
  • Fundamental
  • Price
  • CNTX $1.30
  • FBYD $9.41
  • Analyst Decision
  • CNTX Strong Buy
  • FBYD
  • Analyst Count
  • CNTX 3
  • FBYD 0
  • Target Price
  • CNTX $6.83
  • FBYD N/A
  • AVG Volume (30 Days)
  • CNTX 210.1K
  • FBYD 16.1K
  • Earning Date
  • CNTX 11-06-2024
  • FBYD 11-14-2024
  • Dividend Yield
  • CNTX N/A
  • FBYD N/A
  • EPS Growth
  • CNTX N/A
  • FBYD N/A
  • EPS
  • CNTX N/A
  • FBYD N/A
  • Revenue
  • CNTX N/A
  • FBYD $7,042,000.00
  • Revenue This Year
  • CNTX N/A
  • FBYD N/A
  • Revenue Next Year
  • CNTX N/A
  • FBYD N/A
  • P/E Ratio
  • CNTX N/A
  • FBYD N/A
  • Revenue Growth
  • CNTX N/A
  • FBYD N/A
  • 52 Week Low
  • CNTX $0.77
  • FBYD $7.02
  • 52 Week High
  • CNTX $2.75
  • FBYD $12.93
  • Technical
  • Relative Strength Index (RSI)
  • CNTX 25.94
  • FBYD 48.58
  • Support Level
  • CNTX $1.56
  • FBYD $8.51
  • Resistance Level
  • CNTX $2.32
  • FBYD $9.87
  • Average True Range (ATR)
  • CNTX 0.16
  • FBYD 0.63
  • MACD
  • CNTX -0.07
  • FBYD 0.01
  • Stochastic Oscillator
  • CNTX 17.88
  • FBYD 58.44

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

About FBYD Falcon's Beyond Global Inc.

Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has five operating segments, Falcon's Creative Group, PDP, Sierra Parima, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.

Share on Social Networks: